FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Zhirong Zhan

Research Profile

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Robert W Robey; Zhirong Zhan; Julian Bahr; Agnes Basseville; Arup R Chakraborty; Victoria Luchenko; Susan E Bates
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Kenneth K W To; Robert W Robey; Zhirong Zhan; Lois Bangiolo; Susan E Bates
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.
Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Zhirong Zhan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Robert W Robey; Zhirong Zhan; Julian Bahr; Agnes Basseville; Arup R Chakraborty; Victoria Luchenko; Susan E Bates
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Molecular pharmaceutics 2011;8(6):2021-31.
2011: Kenneth K W To; Robert W Robey; Zhirong Zhan; Lois Bangiolo; Susan E Bates
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway.
Molecular cancer research : MCR 2011;9(4):516-27.
2010: Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
British journal of haematology 2010;148(2):256-67.
2009: Kenneth K W To; Robert W Robey; Turid Knutsen; Zhirong Zhan; Thomas Ried; Susan E Bates
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.
Molecular cancer therapeutics 2009;8(10):2959-68.
2008: Kenneth K W To; Zhirong Zhan; Thomas Litman; Susan E Bates
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.
Molecular and cellular biology 2008;28(17):5147-61.
2006: Robert W Robey; Zhirong Zhan; Richard L Piekarz; Ganesh L Kayastha; Tito Fojo; Susan E Bates
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1547-55.
2004: Richard L Piekarz; Robert W Robey; Zhirong Zhan; Ganesh L Kayastha; Anousheh Sayah; Amina H Abdeldaim; Sonia Torrico; Susan E Bates
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Blood 2004;103(12):4636-43.
2002: Thomas Litman; Ulla Jensen; Alastair Hansen; Kuang-Ming Covitz; Zhirong Zhan; Patricia A Fetsch; Andrea Abati; Paul Robert Hansen; Thomas Horn; Torben Skovsgaard; Susan E Bates
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.
Biochimica et biophysica acta 2002;1565(1):6-16.
2001: Masaki Kitazono; Robert W Robey; Zhirong Zhan; Nicholas Sarlis; Monica C Skarulis; Takashi Aikou; Susan Bates; Tito Fojo
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
The Journal of clinical endocrinology and metabolism 2001;86(7):3430-5.
2000: Yutaka Chuman; Zhirong Zhan; Tito Fojo
Construction of gene therapy vectors targeting adrenocortical cells: enhancement of activity and specificity with agents modulating the cyclic adenosine 3',5'-monophosphate pathway.
The Journal of clinical endocrinology and metabolism 2000;85(1):253-62.
1999: Susan E Bates; Zhirong Zhan; J Regis; E Gamelin
Measuring MDR-1 by Quantitative RT-PCR.
Methods in molecular medicine 1999;28():63-81.
1999: K Miyake; Lyn A Mickley; Thomas Litman; Zhirong Zhan; Robert W Robey; B Cristensen; M Brangi; Lee M Greenberger; Michael Dean; Tito Fojo; Susan E Bates
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Cancer research 1999;59(1):8-13.
1998: Mikhail V Blagosklonny; A Iglesias; Zhirong Zhan; Tito Fojo
Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs.
Biochemical and biophysical research communications 1998;244(2):368-73.
1998: Lyn A Mickley; Jong-Seok Lee; Z Weng; Zhirong Zhan; M Alvarez; W Wilson; Susan E Bates; Tito Fojo
Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.
Blood 1998;91(5):1749-56.
1997: J S Lee; S Scala; Y Matsumoto; B Dickstein; Robert W Robey; Zhirong Zhan; G Altenberg; Susan E Bates
Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Journal of cellular biochemistry 1997;65(4):513-26.
1997: Zhirong Zhan; Victor A Sandor; E Gamelin; JT Regis; B Dickstein; W Wilson; Antonio Tito Fojo; Susan E Bates
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Blood 1997;89(10):3795-800.
1997: Zhirong Zhan; S Scala; Anne Monks; Curtis Hose; S Bates; T Fojo
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.
Cancer chemotherapy and pharmacology 1997;40(3):245-50.
1996: Susan E Bates; Wyndham H Wilson; Antonio Tito Fojo; M Alvarez; Zhirong Zhan; JT Regis; Robert W Robey; C Hose; Anne Monks; Y K Kang; B Chabner
Clinical reversal of multidrug resistance.
Stem cells (Dayton, Ohio) 1996;14(1):56-63.
1995: Y K Kang; Zhirong Zhan; JT Regis; M Alvarez; Robert W Robey; Beverly Meadows; B Dickstein; J S Lee; T Otsuki; Maryalice Stetler-Stevenson
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
Blood 1995;86(4):1515-24.
1995: Wyndham H Wilson; Susan E Bates; Antonio Tito Fojo; G Bryant; Zhirong Zhan; JT Regis; Robert Wittes; Elaine S Jaffe; Seth M Steinberg; J Herdt
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1995-2004.
1995: S Scala; Alfredo Budillon; Zhirong Zhan; Yoon S Cho-Chung; J Jefferson; M Tsokos; Susan E Bates
Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.
The Journal of clinical investigation 1995;96(2):1026-34.
1994: Susan E Bates; JT Regis; Robert W Robey; Zhirong Zhan; S Scala; Beverly Meadows
Chemoresistance in the clinic: overview 1994.
Bulletin du cancer 1994;81 Suppl 2():55s-61s.
1994: Susan E Bates; Zhirong Zhan; B Dickstein; J S Lee; S Scala; Antonio Tito Fojo; KD Paull; W Wilson
Reversal of multidrug resistance.
Journal of hematotherapy 1994;3(3):219-23.
1994: Susan E Bates; Zhirong Zhan; B Dickstein; J S Lee; S Scala; Antonio Tito Fojo; KD Paull; W Wilson
Reversal of multidrug resistance.
Progress in clinical and biological research 1994;389():33-7.